India, Sept. 5 -- image credit- freepik

Mumbai-based Sun Pharmaceutical Industries joined several pharmaceutical companies at a White House ceremony to announce agreements with the US government aimed at prioritising access to affordable medicines for millions of American patients.

As part of its agreement, Sun Pharma will extend Most Favored Nation (MFN) pricing to state Medicaid programmes. Sun Pharma also commits to MFN pricing for future innovative medicine launches. The agreement recognises Sun Pharma's investment in the US market by delaying Section 232 tariffs on innovative pharmaceutical products for over two years.

Sun Pharma initially built its US presence on a foundation of high-quality generics followed by an increasing emp...